Lake Street lowered the firm’s price target on OptimizeRx (OPRX) to $11 from $15 and keeps a Buy rating on the shares. Revenue came in roughly $3.7M short of the $25.0M consensus, mainly due to a shortfall in the DTC Medicx business, the analyst tells investors. The company is implementing changes to its 2025 plan with greater focus on self-serve, which should alleviate some of the softness in the DTC business, but the company lowered its 2024 outlook to account for the change, the analyst added.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target lowered to $16 from $20 at Roth MKM
- OptimizeRx price target lowered to $8 from $16 at JMP Securities
- OptimizeRx price target lowered to $5 from $11 at Barclays
- OptimizeRx Reports Strong Revenue Growth in Q3 2024
- Closing Bell Movers: Tetra Tech down 8% after Q4 results, guidance